Grants per year
Personal profile
Research Interests
I have an interest in the development of clinical trials, as well as studying novel biomarkers that may be used as prognostic and predictive tools in the management of melanoma and other advanced skin cancers, as well as cancer of unknown primary.
Training Experience
| 2011 | Residency, Case Western Reserve University Hospital |
| 2014 | Fellowship, New York University Medical Center |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
MD, Medicine, Michigan State University
… → 2008
MS, Michigan State University
… → 2003
Research interests keywords
- Cancer of Unknown Primary
- Clinical Research
- Drug Discovery
- Melanoma
- Skin Cancer
Fingerprint
Dive into the research topics where Sunandana Chandra is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #RP2-202: A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint InhibitorNaïve Adult Patients with Metastatic Uveal M
Chandra, S. (PD/PI)
3/28/25 → 3/28/28
Project: Research project
-
Prot #RP1-104: A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician’s Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 an
Chandra, S. (Co-PD/PI)
3/17/25 → 3/17/28
Project: Research project
-
Improving Mucosal Melanoma Therapy by Harnessing the Immunogenicity of r3LCMV - Pollack Lab
Pollack, S. M. (PD/PI), Alexiev, B. A. (Co-Investigator), Chandra, S. (Co-Investigator), Chen, R. (Co-Investigator), Jing, W. (Co-Investigator) & Obeidin, F. (Co-Investigator)
1/1/25 → 12/31/29
Project: Research project
-
Prot #IMC-F106C-301: A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Chandra, S. (PD/PI)
Worldwide Clinical Trials, Inc., Immunocore Limited
9/30/24 → 9/30/27
Project: Research project
-
Prot #MT-8421-001: A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-8421 as Monotherapy and in Combination with Nivolumab in Patients wit
Chandra, S. (PD/PI)
6/21/24 → 6/21/27
Project: Research project
-
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6
Hughes, B. G. M., Guminski, A., Bowyer, S., Migden, M. R., Schmults, C. D., Khushalani, N. I., Chang, A. L. S., Grob, J. J., Lewis, K. D., Ansstas, G., Day, F., Ladwa, R., Stein, B. N., Muñoz Couselo, E., Meier, F., Hauschild, A., Schadendorf, D., Basset-Seguin, N., Modi, B. & Dalac-Rat, S. & 24 others, , Jan 2025, In: Journal of the American Academy of Dermatology. 92, 1, p. 68-77 10 p.Research output: Contribution to journal › Article › peer-review
10 Scopus citations -
Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma
McGillivray, E., Ashouri, K., Chatziioannou, E., Gallegos, J. A. O., Zarka, J., Kechter, J., Hwang, A. S., Zhang, K., Barros, M., Yeh, J., Okazaki, I., Crocker, A. B., Maeda, T., Park, S. J., Choi, J., Andreoli, M., Darwish, T., Savage, D. J., Kim, K. B. & Gupta, J. & 24 others, , Feb 1 2025, In: British Journal of Dermatology. 192, 2, p. 316-326 11 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
Lee, S. M., Hamid, O., Jotte, R., Zakharia, Y., Medina, T., Gillespie-Twardy, A., Mehmi, I., Chandra, S., Watson, G., Ward, P., Chaney, M., Lu, H., Berndt, J., O’Connor, B. P., Rathi, K., Shaikh, E. & Cowey, C. L., Mar 1 2025, In: Clinical Cancer Research. 31, 5, p. 848-859 12 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
Real-world outcomes in patients with melanoma brain metastasis: a US multisite retrospective chart review study of systemic treatments
Glitza Oliva, I. C., Palaia, J., Sakkal, L. A., Patel, D., Moshyk, A., Han, N., Odak, S., Schmier, J. K., Ning, N. & Chandra, S., Jan 30 2025, In: BMJ open. 15, 1, e091098.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Recommended guidelines for screening for underlying malignancy in extramammary Paget's disease based on anatomic subtype
Extramammary Paget's Disease Guideline Study Group, Feb 2025, In: Journal of the American Academy of Dermatology. 92, 2, p. 261-268 8 p.Research output: Contribution to journal › Article › peer-review